MEGLUMINE ANTIMONIATE, pentaval. antimony 81 mg/ml, 5ml, amp
STD
DINJMEGA4A-
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
02/05/2024, 22:05:30
6.5.2 - Antileishmaniasis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01CB01
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
MEGLUMINE antimoniate
- In the WHO list of Essential Medicines 2023 (1.5 g/5 mL in 5 mL ampoule)
Therapeutic Action
Indications
Cutaneous and mucocutaneous leishmaniasis
Some restricted information has been hidden. Sign in
to see this information
Instructions for use
Follow the national or WHO protocol.
81 mg/ml pentavalent antimony is equivalent to 0.3 g/ml meglumine antimoniate.
The 5 ml ampoule contains 1.5 g of meglumine antimoniate.
Must be given as IM injection.
Precautions for Use
Contreindicated in patients with renal, cardiac or hepatic impairment.
Storage
- Below 25ºC
- After opening, use the product immediately.